Can vitamin D delay the progression of ALS?

Medical Hypotheses

Volumn 76, Issue 5, 2011, Pages 643-645

  Karam, Chafic ^a   Scelsa, Stephen N ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; SOMATOMEDIN C; VASCULOTROPIN; VITAMIN D;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DISEASE COURSE; DRUG SAFETY; GLIOSIS; HUMAN; MOTONEURON; NERVE REGENERATION; NONHUMAN; OCULOMOTOR NERVE;

AMYOTROPHIC LATERAL SCLEROSIS; AXONS; CALCIUM; DISEASE PROGRESSION; GLIOSIS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MODELS, THEORETICAL; MOTOR NEURONS; NERVE REGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN D;

EID: 79954419546     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.01.021     Document Type: Article

References (33)

1. Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009, 4:3.
2. Shaw P.J. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry 2005 Aug, 76(8):1046-1057.
3. Miller, R.G., Mitchell, J.D., Lyon, M., and Moore, D.H. (2007). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. CD001447.
4. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001, 28(2):131-138.
5. Elliott J.L., Snider W.D. Motor neuron growth factors. Neurology 1996, 47(4 Suppl. 2):S47-53.
6. Papadimitriou D., Le Verche V., Jacquier A., Ikiz B., Przedborski S., Re D.B. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis 2010, 37(3):493-502. Epub. 2009 Oct 13.
7. Bergmann M., Völpel M., Kuchelmeister K. Onuf's nucleus is frequently involved in motor neuron disease/amyotrophic lateral sclerosis. J Neurol Sci 1995 Apr, 129(2):141-146.
8. Alexianu M.E., Ho B.K., Mohamed A.H., La Bella V., Smith R.G., Appel S.H. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994 Dec, 36(6):846-858.
9. Ince, Stout N., Shaw P., Slade J., Hunziker W., Heizmann C.W., et al. Parvalbumin and calbindin D-28K in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993, 19:291-299.
10. Morrison B.M., Gordon J.W., Ripps M.E., Morrison J.H. Quantitative immunocytochemical analysis of the spinal cord in G86R superoxide dismutase transgenic mice: neurochemical correlates of selective vulnerability. J Comp Neurol 1996, 373(4):619-631.
11. Elliott J.L., Snider W.D. Parvalbumin is a marker of ALS-resistant motor neurons. Neuroreport 1995, 6(3):449-452.
12. Beers D.R., Ho B.K., Siklós L., Alexianu M.E., Mosier D.R., Mohamed A.H., et al. Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J Neurochem 2001 Nov, 79(3):499-509.
13. Alexianu M.E., Robbins E., Carswell S., Appel S.H. 1Alpha, 25 dihydroxyvitamin D3-dependent up-regulation of calcium-binding proteins in motoneuron cells. J Neurosci Res 1998, 51(1):58-66.
14. Kawamata T., Akiyama H., Yamada T., McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992 Mar, 140(3):691-707.
15. Ince P.G., Shaw P.J., Slade J.Y., Jones C., Hudgson P. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol 1996 Oct, 92(4):395-403.
16. Hensley K., Fedynyshyn J., Ferrell S., Floyd R.A., Gordon B., Grammas P., et al. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 2003 Oct, 14(1):74-80.
17. Elliott J.L. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 2001, 95(1-2):172-178.
18. Yrjänheikki J., Tikka T., Keinänen R., Goldsteins G., Chan P.H., Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999, 96(23):13496-13500.
19. Kriz J., Nguyen M.D., Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002 Aug, 10(3):268-278.
20. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002 Dec, 52(6):771-778.
21. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., et al. Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6(12):1045-1053.
22. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006, 60(1):22-31.
23. Szodoray P., Nakken B., Gaal J., Jonsson R., Szegedi A., Zold E., et al. The complex role of vitamin D in autoimmune diseases. Scand J Immunol 2008 Sep, 68(3):261-269.
24. Chabas J.F., Alluin O., Rao G., Garcia S., Lavaut M.N., Risso J.J., et al. Vitamin D2 potentiates axon regeneration. J Neurotrauma 2008 Oct, 25(10):1247-1256.
25. Devos D., Moreau C., Lassalle P., Perez T., De Seze J., Brunaud-Danel V., et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004, 62:2127-2129.
26. Cardus A., Panizo S., Encinas M., Dolcet X., Gallego C. Aldea Met al 1, 25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009 May, 204(1):85-89.
27. Oppenheim R.W. Neurotrophic survival molecules for motoneurons: an embarrassment of riches. Neuron 1996 Aug, 17(2):195-197.
28. Lepore A.C., Haenggeli C., Gasmi M., Bishop K.M., Bartus R.T., Maragakis N.J., et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res 2007, 1185:256-265.
29. Franz C.K., Federici T., Yang J., Backus C., Oh S.S., Teng Q., et al. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol. Dis. 2009, 33:473-481.
30. Gómez J.M. The role of insulin-like growth factor I components in the regulation of vitamin D. Curr Pharm Biotechnol 2006 Apr, 7(2):125-132.
31. Hathcock J.N., Shao A., Vieth R., Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007, 85:6-18.
32. Vieth R., Chan P.C., MacFarlane G.D. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001 Feb, 73(2):288-294.
33. Burton J.M., Kimball S., Vieth R., Bar-Or A., Dosch H.M., Cheung R., et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74(23):1852-1859.